Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test change how doctors treat Alzheimer's? new study investigates

NCT ID NCT07099001

Knowledge-focused Sponsor: Qure Healthcare, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving doctors educational materials about a new blood test for Alzheimer's disease helps them make better care decisions. 178 neurologists and dementia specialists in the US participated in virtual patient cases. The researchers measured changes in diagnosis and treatment recommendations after doctors received the educational materials and test results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that educating doctors about a new blood test improves how they diagnose and manage Alzheimer's disease.
What could go wrong
This is a small, completed study using virtual patients, not real ones. The results may not reflect how doctors would act in actual clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

178 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified in neurology for at least two years (and no more than 35 years * Average at least 20 hours per week of clinical and patient care duties over the past six months * Routinely evaluate patients at risk for Alzheimer's disease * Practicing in the United States * Able to read English * Access to the internet * Not participating in a clinical research study of the AD assay * Informed, signed, and voluntarily consented to participate in this study Exclusion Criteria: * Board-certified in neurology for less than two years * Board certification in neurology over 35 years ago * Unable to read English * Unable to access the internet * Not practicing in the United States * Not averaging at least 20 hours per week of clinical or patient care duties over the past six months * Participating in a clinical research study of the AD assay * Do not voluntarily consent to participate in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease (AD) Cognitive decline

Contacts and locations

Locations

  • QURE Healthcare

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.